Fong James K

EVP & Chief Commercial OfficerCTI BIOPHARMA CORP (CTIC) · full profile →Form 4 · filed Jun 26, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
1 non-derivative · 9 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 26, 2023Tender(U)4K$9.10$32K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 26, 2023Disposed to issuer(D)200K0
Jun 26, 2023Disposed to issuer(D)23K0
Jun 26, 2023Disposed to issuer(D)210K0
Jun 26, 2023Disposed to issuer(D)10K0
Jun 26, 2023Disposed to issuer(D)8K0
Jun 26, 2023Disposed to issuer(D)59K0
Jun 26, 2023Disposed to issuer(D)188K0
Jun 26, 2023Disposed to issuer(D)210K0
Jun 26, 2023Disposed to issuer(D)115K0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-23-016479) within minutes of acceptance. Every field above traces to the original document. Verify it directly: